Press Releases

Sosei Group Corporation (“the Company”; TSE: 4565), notes its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies. The studies are designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1117569 and NBI-1117567 in healthy adult participants. NBI-1

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival (PFS), demonstrating a statisticall

Vetter, a leading globally operating Contract Development and Manufacturing Organization (CDMO), has joined the Science Based Targets Initiative (SBTi) membership group as of November 2023. The goal of the companies in the SBTi is to achieve climate neutrality by 2050, thus representing the strictest climate protection targets for companies worldwide. As a result, Vetter has committed to the 1.5 degrees of global warming target. To this end, the CDMO has presented a sustainability strategy wi

Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V.  Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura&rsq

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcinoma (NPC) showed two ongoing confirmed partial responses (PRs) at higher

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic and neuropsychiatric disorders, has released new data from artificial intelligence (AI) simulations that show that, compared to plant-based medical marijuana, there may be significant potential advantages to the therapeutic potential of MIRA1a, such as its potential to offer a superior anti-anxiety treatment, increased cognition

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (“Strides”) today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023. Icosapent ethyl acid soft gel capsules 0.5g and 1g is an ethyl e

NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system ("CNS") disorders, today announced that NLS has entered into an exclusive worldwide option agreement with Aexon Labs, Inc., a privately held U.S. company ("Aexon Labs"), under which NLS may acquire global dev

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T1D) through delaying the onset and/or progression of the disease, today announced that the first participants of a HUMAN trial (Fully HUman anti-thymocyte biologic in first-in-MAN clinical study) have been dosed in Australia. This Phase 1 randomized, double-blin